- All
- 2024
- 2023
- 2022
- 2021
- 2020
- 2019
- 2018
- 2017
- 2016
- 2015
Highlights of AmoyDx FY2023 Financial Report
Amoy Diagnostics Co., Ltd (AmoyDx SZSE: 300685) reported its financial results for the fiscal year 2023.
Revolutionizing Cancer Care in Vietnam: AmoyDx, BCE Vietnam and VSPC Sign MOU to Launch Overseas Molecular Pathology Training Initiative
AmoyDx and BCE Vietnam had signed a Memorandum of Understanding (MOU) with the Vietnam Society of Pathology and Cytology (VSPC) to launch an independent educational initiative committed to Overseas Molecular Pathology Training.
AmoyDx® PD-L1 (E1L3N) assay gained the priority recommendation from Chinese expert consensus
The AmoyDx®PD-L1 (E1L3N) assay was prioritized as companion diagnostics for Pembrolizumab.
AmoyDx has successfully held the 2023 Distributors Annual Meeting at the headquarter in Xiamen, China, on January 22-23, 2024
AmoyDx has successfully held the 2023 Distributors Annual Meeting at the headquarter in Xiamen, China, on January 22-23, 2024
LC-SCRUM's 10-Year Milestone: Amoy Diagnostics Earns International Recognition for Excellence
Dr. Limou Zheng, Founder of Amoy Diagnostics, and Mr. Frank Zheng, Chief Operating Officer, were invited to give a keynote speech at the 10th-anniversary conference of the Asian Lung Cancer Genome Screening Project (LC-SCRUM)
Highlights of China International Import Expo (CIIE) 2023 - Amoy Diagnostics Announced Multiple Collaborations with AstraZeneca and Pfizer
AmoyDx announced multiple collaborations with AstraZeneca and Pfizer during the 2023 China International Import Expo (CIIE), held on November 5-10 in Shanghai China. These partnerships aim to jointly promote the development of precision diagnostics
AmoyDx® Microsatellite Instability (MSI) Detection Kit Received NMPA Approval for Pan-Tumor Immunotherapy Companion Diagnostics
National Medical Products Administration (NMPA) granted approval to AmoyDx® Microsatellite Instability (MSI) Detection Kit
AmoyDx Collaborates with AstraZeneca to Develop a HER2 Companion Diagnostic for Lung Cancer in China
We are thrilled to announce that AmoyDx reaches a new collaboration agreement with AstraZeneca. Under this agreement, the AmoyDx® Essential NGS panel will be used as a companion diagnostic of ENHERTU® to identify HER2 (ERBB2) mutations in patients with no
AmoyDx Signed a Collaboration Agreement with AstraZeneca for HRD Companion Diagnostic
Amoy Diagnostics Co., Ltd (AmoyDx), a China-based innovative molecular diagnostics company (SZSE: 300685), announced that it has entered into a Companion Diagnostic Collaboration Agreement with AstraZeneca (LSE/STO/Nasdaq: AZN), a global biopharmaceutical
AmoyDx® Pan Lung Cancer PCR Panel Approved in Japan as a Companion Diagnostic for selpercatinib RET fusion positive NSCLC
The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyDx PLC Panel”) as a companion diagnostic for RET fusion-positive non-small cell lung cancer (“NSCLC”), for selpercatinib capsules 40 mg
Career Opportunities - Business Manager (EMEA)
You are looking for opportunities to bring to use your knowledge of and experience in oncology molecular diagnostics in qPCR and Next Generation Sequencing application? You are passionate in building meaningful relationship with both internal and external
Career Opportunities - The Field Application Scientist
The Field Application Scientist is responsible for system usage training at customer sites while providing PCR/NGS experimental design, data analysis, logistical, and troubleshooting support for LATAM.
AmoyDx® Pan Lung Cancer PCR Panel Approved in Japan as a Companion Diagnostic for LUMAKRAS® (Sotorasib)
Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyD
AmoyDx and BeiGene Announce Strategic Cooperation on HER2 Companion Diagnostics
Amoy Diagnostics (300685.SZ) and BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) announced a strategic partnership in the field of companion diagnostics.
Amoy Diagnostics and Roche Pharma China Jointly Announce Strategic Partnership
The 2nd Roche Pan-Tumor Precision Medicine Innovation Forum was officially held at the Shanghai Roche Pharmaceuticals Campus, where participants had discussions on recent progresses in this field.
AmoyDx® Master Panel--Study Reveals Clinically Relevant Intertumoral Heterogeneity of NSCLCs Driven by MET Exon 14 Skipping Mutation
Vienna – Aug. 7th, 2022. – A study presented at the IASLC World Conference on Lung Cancer 2022 in Vienna disclosed the clinically relevant intertumoral heterogeneity of non-small cell lung cancer (NSCLC) driven by MET exon 14 skipping (METex14 skipping).
MHLW Approves AmoyDx® Pan Lung Cancer PCR Panel as Companion Diagnostic for Rozlytrek® (Entrectinib) in Japan
TOKYO and XIAMEN, August 9, 2022 -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyDx PLC Panel”) had been approved by t
Filing Notice for a Manufacturing and Marketing Application for AmoyDx® Pan Lung Cancer PCR Panel as a Companion Diagnostic for a Drug Targeting RET fusion-Positive Non-Small Cell Lung Cancer
TOKYO and XIAMEN, April 20, 2022 -- Riken Genesis Co., Ltd., (“Rigen Genesis”), Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that in April 2022, AmoyDx® Pan Lung Cancer PCR Panel (the “